Selecting lncRNAs in gastric cancer cells for directed therapy with bioactive peptides and chemotherapy drugs
Metrics: PDF 1083 views | HTML 1775 views | ?
Wenyan Han1,*, Rui Xiao2,*, Chuanling Zhang3, Qimuge Suyila1, Xian Li1 and Xiulan Su1
1Clinical Medical Research Center of The Affiliated Hospital, Inner Mongolia Medical University, Hohhot 010050, Inner Mongolia Autonomous Region, P.R. China
2Inner Mongolia Key Laboratory of Molecular Pathology, Inner Mongolia Medical University, Huhhot 010059, Inner Mongolia Autonomous Region, P.R. China
3Department of Pharmacy, Inner Mongolia Medical University, Huhhot 010110, Inner Mongolia, P.R. China
*These authors contributed equally to this article and should be regarded as joint first authors
Xiulan Su, email: email@example.com
Keywords: gastric cancer, anti-cancer bioactive peptide, lncRNAs, profile
Received: June 10, 2017 Accepted: August 26, 2017 Published: September 18, 2017
Selecting lncRNAs for directed therapy with bioactive peptides and chemotherapy drugs may be an effective approach to treating gastric cancer (GC). We show genome-scale identification and characterization of differentially expressed lncRNAs in GC cells treated with a novel anti-cancer bioactive peptide (ACBP) and the chemotherapy drug oxaliplatin (ASLB). A total of 17,897 lncRNAs were identified through pairwise comparison, including 2,074 novel lncRNAs. Of those, 1,386 lncRNAs were differentially expressed (over 1.5-fold change vs. control, q-value < 0.05) in response to ACBP and ASLB treatment. These included 914 upregulated and 472 downregulated lincRNAs. Functional annotation of these lncRNAs through Kyoto Encyclopedia of Genes and Genome (KEGG) pathway analysis revealed they activate metabolic pathways and protein-binding processes. Moreover, suppression of the DNA replication process and upregulation of AMP-activated protein kinase (AMPK) signaling in MKN45 cells exposed to ACBP alone or in combination with ASLB was predicted by hierarchical clustering analysis. By providing new insight into the transcriptomic effects of ACBP and ASLB in GC cells, these results provide the first evidence of ACBP inhibition of lincRNAs and may provide new mechanisms of action for ACBP and ASLB.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.